Bristol-Myers Wins U.K. Nod for Melanoma Drug Despite Cost
- Recommendation follows NICE rejection for use in lung cancer
- Final draft guidance is being reviewed by consultation group
This article is for subscribers only.
Bristol-Myers Squibb Co. won the endorsement of the U.K.’s health-cost regulator for the use of its drug Opdivo in skin-cancer patients after failing to win its recommendation for treating lung tumors.
Once the National Institute for Health and Care Excellence makes a final recommendation on Opdivo, the National Health Service must make the medicine available within three months.